Search research articles
Contact Us
Filters
Showing results (81-90 of 139) with videos related to
Page
of 14
Sort By:
Plos One
|
March 11, 2011
The large zinc finger protein ZAS3 is a critical modulator of osteoclastogenesis
Shujun Liu, Francesca Madiai, Kevin V Hackshaw, et al.
Cancers
|
November 27, 2024
Tumor-Associated Edema in Children with Kaposi Sarcoma: 14 Years' Experience at Kamuzu Central Hospital, Lilongwe, Malawi
Fatsani Rose Manase, Allison Silverstein, William Kamiyango, et al.
Pediatric Blood & Cancer
|
April 24, 2012
Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab
Rebecca A Marsh, Carl E Allen, Kenneth L McClain, et al.
Frontiers in Oncology
|
June 28, 2024
Rapid gene fusion testing using the NanoString nCounter platform to improve pediatric leukemia diagnoses in Sub-Saharan Africa
Julie M Gastier-Foster, Fredrick Lutwama, Olive Mbabazi, et al.
Blood
|
October 19, 2020
Overcoming T-cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH
Amel Sengal, Jessica Velazquez, Meryl Hahne, et al.
British Journal of Haematology
|
March 19, 2024
Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis
Vivekanudeep Karri, Howard Lin, Jessica Velazquez, et al.
Blood Advances
|
January 1, 2024
Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study
Birte Wistinghausen, Keri Toner, Donald A Barkauskas, et al.
HIV Medicine
|
October 11, 2021
Long-term outcomes for children and adolescents with Kaposi sarcoma
Allison Silverstein, William Kamiyango, Jimmy Villiera, et al.
Blood
|
September 23, 2017
A genome-wide association study of LCH identifies a variant in <i>SMAD6</i> associated with susceptibility
Erin C Peckham-Gregory, Rikhia Chakraborty, Michael E Scheurer, et al.
Pediatric Blood & Cancer
|
November 3, 2016
A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis
Robert J Arceci, Carl E Allen, Ira J Dunkel, et al.
Page
of 14
Search research articles
Search
Showing results (81-90 of 139) with videos related to
Sort By:
Page
of 14
Plos One
|
March 11, 2011
The large zinc finger protein ZAS3 is a critical modulator of osteoclastogenesis
Shujun Liu, Francesca Madiai, Kevin V Hackshaw, et al.
Cancers
|
November 27, 2024
Tumor-Associated Edema in Children with Kaposi Sarcoma: 14 Years' Experience at Kamuzu Central Hospital, Lilongwe, Malawi
Fatsani Rose Manase, Allison Silverstein, William Kamiyango, et al.
Pediatric Blood & Cancer
|
April 24, 2012
Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab
Rebecca A Marsh, Carl E Allen, Kenneth L McClain, et al.
Frontiers in Oncology
|
June 28, 2024
Rapid gene fusion testing using the NanoString nCounter platform to improve pediatric leukemia diagnoses in Sub-Saharan Africa
Julie M Gastier-Foster, Fredrick Lutwama, Olive Mbabazi, et al.
Blood
|
October 19, 2020
Overcoming T-cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH
Amel Sengal, Jessica Velazquez, Meryl Hahne, et al.
British Journal of Haematology
|
March 19, 2024
Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis
Vivekanudeep Karri, Howard Lin, Jessica Velazquez, et al.
Blood Advances
|
January 1, 2024
Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study
Birte Wistinghausen, Keri Toner, Donald A Barkauskas, et al.
HIV Medicine
|
October 11, 2021
Long-term outcomes for children and adolescents with Kaposi sarcoma
Allison Silverstein, William Kamiyango, Jimmy Villiera, et al.
Blood
|
September 23, 2017
A genome-wide association study of LCH identifies a variant in <i>SMAD6</i> associated with susceptibility
Erin C Peckham-Gregory, Rikhia Chakraborty, Michael E Scheurer, et al.
Pediatric Blood & Cancer
|
November 3, 2016
A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis
Robert J Arceci, Carl E Allen, Ira J Dunkel, et al.
Page
of 14